A unique business model for success: in-license, add value through innovative R&D strategy and implementation, out-license and maximise commercialisation potential

We are a highly focused NRDO (no research development only) organisation that specialises in the drug development process, successfully bringing novel biopharmaceuticals to market. Our business strategy is to partner through the in-licensing of therapeutic products from biotechnology, pharmaceutical and academic organisations worldwide. We develop the products while paving the way to global registration and we carefully select optimal marketing partners to maximise commercialisation.

Enhancing the development process of biopharmaceuticals

We bring together more than 25 years of expertise and dedicated multidisciplinary teams to achieve timely regulatory- and marketdriven pharmaceutical development programs. Our experience has been validated by the rapid development and out-licensing of three commercially successful products that are top performers in their specific therapeutic areas; Eloxatin®, Trelstar® and Decapeptyl®.

By maximising the commercial potential of all our partnered therapeutic products, we are not only able to share in the success with our partners and the inventors, but also to reinvest the commercial proceeds into the development of a new generation of products and partnerships.